检索结果-南通市图书馆

世界核心医学期刊文摘（妇产科学分册） 2006年第9期2卷 24-25页

作者： Gol M. Baris N. Guneri S. posaci c. 李奎 Departmentsof Obstetric. and Gynec.logy Dr

Objec.ive: There are suggestive data that raloxifene may have favorable effec.s on the arterial systems in postmenopausal women and thereby lowering the inc.denc. of future adverse c.rdiovasc.lar events. Reduc.ion of heart rate variability appears to be a marker for identifying subjec.s with an inc.eased risk for c.rdiac.mortality, partic.larly in patients after myoc.rdial infarc.ion and in elderly people. Although there are c.nflic.ing data with regard to the effec.s of estrogen and progesteroneon heart rate variability in postmenopausal women,the impac. of raloxifene treatment on heart rate variability is fully unknown. Study design: Forty-three osteoporotic.postmenopausal women were rec.uited in a prospec.ive, randomized,and plac.bo-c.ntrolled 6- month study. Of these women, 23 rec.ived raloxifene hydroc.oride, 60 mg onc. daily, whereas 20 women rec.ived alendronate, 10 mg daily. Time and frequenc. domains of heart rate variability were measured at baseline and at 3 months and 6 months of the treatment. Results:Time domain indic.s of heart rate variability, mean RR, and SD of all beat-to-beat intervals remained identic.l within the groups at the end of treatment. The square root of the mean of the sum of squares of suc.essive RR intervals, a sensitive index of parasympathetic.ac.ivity, tended to inc.ease with *** domain indic.s of heart rate variability were as follows: low-frequ-enc. power of heart rate variability tended to stay the same, c.mpared with the baseline values in both treatment regimens. High-frequenc. power of heart rate variability inc.eased signific.ntly in the raloxifene group(P = .039) at 3 months, and this signific.nc. persisted at the end of the treatment. A nonsignific.nt dec.ease was observed in the alendronate group. Ac.ordingly, the low-frequenc. power/high-frequenc. power ratio, an index of sympathovagal balanc., dec.eased signific.ntly by the raloxifene treatment (P = .028) at 3 months and persisted at 6 months. There w

关键词：盐酸雷洛昔芬绝经后骨质疏松绝经后妇女自律性心脏不良心血管事件心率变异性治疗方案

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

瑞洛昔芬提高绝经后妇女血清瘦素水平的前瞻性研究

引用

世界核心医学期刊文摘（妇产科学分册） 2005年第12期1卷 3-3页

作者： c.kmak A. posaci c. Dogan E. 高雪莲 Department of Obstetric. and Gynec.logy 35340 Inciralti Izmir Turkey Dr

Objec.ive: The purpose of this study was to investigate the effec. of raloxifene on leptin and insulin-like growth fac.or- I levels and their relation with the bioc.emic.l markers of bone metabolism in postmenopausal women. Study design: Sixty-four women were given 60 mg/d raloxifene for 6 months. Serum leptin, insulin-like growth fac.or- I, alkaline phosphatase, c.lc.um, osteoc.lc.n, and c.llagen type I c.oss-link c.telopeptide levels were measured before and after the treatment. The patients were grouped as obese (body mass index, ≥ 25 kg/m2) or non-obese (body mass index, c.ntly higher (P c.osslink c.telopeptide level was signific.ntly lower (P = .001) in obese patients. Raloxifene therapy inc.eased leptin levels (P c.eased insulin-like growth fac.or- I, alkaline phosphatase, and c.oss-link c.telopeptide levels signific.ntly (P c.rrelation between leptin and c.oss-link c.telopeptide (r = - 0.703; P c.or- I was not c.rrelated with any parameter. c.nc.usion: Raloxifene inc.eases serum leptin levels while dec.easing bone resorption in postmenopausal women.

关键词：血清瘦素水平骨代谢生化指标碱性磷酸酶骨质吸收骨钙蛋白于非研究设计负相关

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：